According to Coherent Market Insights, the Middle East and Turkey hemophilia treatment market to grow 4.2% CAGR

▴ hemophilia treatment
A CAGR of 4.2% during the forecast period (2019-2027), owing to increasing product launches by key players.

Middle East and Turkey hemophilia treatment market is expected to witness significant growth over the forecast period, owing to increasing demand for hemophilia treatment option such as recombinant coagulation factor and plasma-derived coagulation factor concentrates in emerging economies such as Saudi Arabia and Turkey, which is expected to drive the segment growth during the forecast period. For instance, according to the reports published by the World Federation of Hemophilia in 2016, demand for plasma-derived coagulation factors is high compared to recombinant coagulation concentrate. Moreover, plasma-derived coagulation concentrate are easily available in emerging economies such as Turkey and Saudi Arabia.

Moreover, increasing research and development for the development of novel therapies and rising incidence of hemophilia B is expected to drive the market growth. For instance, in August 2019, Mitsubishi Tanabe Pharma and Jichi Medical University entered into a collaboration to launch research study program for the development of gene therapy products, which can be used in the treatment of Hemophilia B. Moreover, according to the World Federation of Hemophilia 2018 statistics, around 1,084 cases of hemophilia B were reported in 2017, in Egypt.

Middle East, Asia Pacific, and Africa are expected to be the potential markets for hemophilia, owing to increasing healthcare awareness along with supportive government initiatives towards patient care and prevention of bleeding disorders. This is expected to create a favorable environment for market players. For instance, in July 2019, UAE Ministry of Health & Prevention (MoHAP) signed a Memorandum of Understanding (MoU) with Swedish Orphan Biovitrum AB Middle East and Bayti Home Healthcare. The initiative is for patients with Hemophilia A and Hemophilia B, who have difficulty in visiting medical centers and, in order to support and improve adherence to the treatment protocols prescribed by the doctors.

Among countries, Israel hemophilia treatment market is expected to witness significant growth over the forecast period, owing to presence of research facilities in Israel, which aids in conducting clinical studies for hemophilia therapy. For instance, in April 2019, Sheba Medical Center, Tel HaShomer, an Israel-based hospital, is the first hospital in Middle East region that conducted phase III trial on humans using the innovative gene therapy developed by the U.S.-based pharmaceutical company.

Tags : #cagr #middleeast #turkey #haemophilia #medicircle

About the Author

Snehangshu Dasgupta,

Managing Editor
[email protected]

Related Stories

Loading Please wait...

Trending Now

Global Coronavirus deaths cross 1 Million markSeptember 28, 2020
Global Coronavirus deaths cross 1 Million markSeptember 28, 2020
Navigation system and Robotics amongst the new trends in spine surgery says Dr. G Amrit, Orthopedic Spine Surgeon  September 28, 2020
WISI Meetings: Sports Management (India)September 28, 2020
Indoco Remedies launches FEVINDO : 400 mg FavipiravirSeptember 28, 2020
Myanmar extends COVID-19 lockdown in 11 new areas ; International flights suspended till Oct 31September 28, 2020
Nagaland, Manipur Covid-19 News Update Sep 28, 2020September 28, 2020
Delhi reports 3,292 fresh cases of COVID-19 , Himachal Pradesh 195September 28, 2020
9543 people test positive for new Covid-19 cases in KarnatakaSeptember 28, 2020
Zymo Research granted CE IVD Mark for sample collection devicesSeptember 28, 2020
India COVID-19 News update Date across States and UT's - September 27 , 2020September 27, 2020
VAXART investigation initiated by former Louisiana Attorney GeneralSeptember 26, 2020
Bangladesh prepares for ‘second wave’ as Corona death crosses 5,000 markSeptember 26, 2020
Thane district in Maharashtra recorded 1,671 new cases of COVID-19September 26, 2020
NPPA decides to cap price of liquid medical oxygen & medical oxygen cylindersSeptember 26, 2020
Mesothelioma September 26, 2020
Highly effective antibodies identified, may lead to passive COVID-19 vaccineSeptember 26, 2020
Europe has a lot of work to do to prevent COVID-19 transmission: WHOSeptember 26, 2020
Some severe COVID-19 cases linked to genetic mutationsSeptember 26, 2020
Two million Coronavirus deaths : WHO September 26, 2020